Grifols S.A
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, u… Read more
Market Cap & Net Worth: Grifols S.A (GIFLF)
Grifols S.A (PINK:GIFLF) has a market capitalization of $4.02 Billion ($4.02 Billion) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #2641 globally and #1834 in its home market, demonstrating a -15.66% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Grifols S.A's stock price $9.53 by its total outstanding shares 422284992 (422.28 Million).
Grifols S.A Market Cap History: 2015 to 2025
Grifols S.A's market capitalization history from 2015 to 2025. Data shows change from $8.97 Billion to $4.02 Billion (-7.80% CAGR).
Grifols S.A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Grifols S.A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.65x
Grifols S.A's market cap is 0.65 times its annual revenue
0.84x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
29.74x
Grifols S.A's market cap is 29.74 times its annual earnings
11.15x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $8.97 Billion | $3.93 Billion | $532.14 Million | 2.28x | 16.86x |
| 2016 | $7.62 Billion | $4.05 Billion | $545.46 Million | 1.88x | 13.96x |
| 2017 | $11.44 Billion | $4.32 Billion | $662.70 Million | 2.65x | 17.27x |
| 2018 | $10.90 Billion | $4.49 Billion | $596.64 Million | 2.43x | 18.27x |
| 2019 | $14.36 Billion | $5.10 Billion | $625.15 Million | 2.82x | 22.97x |
| 2020 | $12.08 Billion | $5.34 Billion | $618.55 Million | 2.26x | 19.53x |
| 2021 | $7.79 Billion | $4.93 Billion | $188.73 Million | 1.58x | 41.26x |
| 2022 | $4.50 Billion | $6.06 Billion | $208.28 Million | 0.74x | 21.62x |
| 2023 | $6.67 Billion | $6.59 Billion | $59.31 Million | 1.01x | 112.49x |
| 2024 | $4.67 Billion | $7.21 Billion | $156.92 Million | 0.65x | 29.74x |
Competitor Companies of GIFLF by Market Capitalization
Companies near Grifols S.A in the global market cap rankings as of March 18, 2026.
Key companies related to Grifols S.A by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $883.37 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #18 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #29 globally with a market cap of $390.88 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #46 globally with a market cap of $296.35 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $883.37 Billion | $989.12 |
| #18 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $243.19 |
| #29 | AbbVie Inc | NYSE:ABBV | $390.88 Billion | $221.45 |
| #46 | AstraZeneca PLC | NASDAQ:AZN | $296.35 Billion | $192.01 |
Grifols S.A Historical Marketcap From 2015 to 2025
Between 2015 and today, Grifols S.A's market cap moved from $8.97 Billion to $ 4.02 Billion, with a yearly change of -7.80%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $4.02 Billion | -13.76% |
| 2024 | $4.67 Billion | -30.06% |
| 2023 | $6.67 Billion | +48.15% |
| 2022 | $4.50 Billion | -42.16% |
| 2021 | $7.79 Billion | -35.54% |
| 2020 | $12.08 Billion | -15.87% |
| 2019 | $14.36 Billion | +31.72% |
| 2018 | $10.90 Billion | -4.75% |
| 2017 | $11.44 Billion | +50.26% |
| 2016 | $7.62 Billion | -15.12% |
| 2015 | $8.97 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Grifols S.A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.02 Billion USD |
| MoneyControl | $4.02 Billion USD |
| MarketWatch | $4.02 Billion USD |
| marketcap.company | $4.02 Billion USD |
| Reuters | $4.02 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.